Last updated: 13.02.2014

Address: Am Klopferspitz 19a
82152 Martinsried, Germany

Tel: +49.(0)89.45244 65-0

Web: http://www.evotec.com/

Company description

Evotec is a leader in the discovery and development of novel small molecule drugs. Both through its own discovery programs and through research collaborations, it is generating the highest quality research results to its partners in the pharmaceutical and biotechnology industries. In proprietary projects, Evotec specializes in finding novel therapies for neuroscience, pain, and inflammation. Evotec’s portfolio comprises five clinical compounds. Evotec has a number of proprietary projects in preclinical development. The Company has substantial drug discovery expertise and an industrialized platform that drives new innovative small molecule compounds through the drug development process. In addition, Evotec has built a deep internal knowledge base in the treatment of diseases related to inflammation, pain and neuroscience. Leveraging these skills and expertise the Company develops best-in-class differentiated therapeutics and delivers superior science-driven discovery alliances with pharmaceutical and biotechnology companies.Evotec has long-term discovery alliances with partners including Boehringer Ingelheim, CHDI, Novartis, Ono Pharmaceutical and Roche. The Company has a P2X7 antagonist for the treatment of inflammatory diseases in clinical development (EVT 401) and a series of preclinical compounds and development partnerships, including a strategic alliance with Roche for EVT 101, a subtype selective NMDA receptor antagonist, for use in treatment-resistant depression.

Products and services


We use cookies to ensure that we give you the best experience on our site. For more info

See our Cookie Privacy Policy Here